Introduction
The limbic lobe is a complex system comprising cortical and subcortical structures. Key structures of the limbic system include the hippocampus, parahippocampus, cingulate gyrus, amygdala, and hypothalamus [1]. The fornix, a connection pathway within the limbic system, is one of the commissural pathways that ensure the relationship between the cerebral hemispheres. The fornix has a semicircular morphology extending from anterior to posterior; its structure comprises four anatomical components: the columns, body, crura, fimbriae, and alveus. The fimbriae and alveus are fused with the hippocampus and extend medially to the temporal horn of the lateral ventricle. During their course, the crura and body are situated in close proximity to the septum pellucidum and internal cerebral veins. The anteriorly located column of the fornix joins with the corpus mamillare [2,3].
Technical advances in neuroimaging have allowed detailed evaluation of the limbic system and fornix. The most important advances in the evaluation of the anatomy and morphology of the limbic system have been in magnetic resonance imaging (MRI). Along with the multi-plane capability and high resolution of MRI, diffusion-weighted and diffusion-tensor imaging techniques have led to a better understanding of the diseases affecting the limbic system [4,5].
The limbic system can be affected by a wide variety of malignant and non-malignant diseases. This critical review delves into the intricacies of fornix involvement in intracranial tumors, aiming to assess the strengths and limitations of existing research while identifying avenues for improvement. Understanding the role of the fornix in cognitive function and its implications for patient management is crucial for enhancing clinical care in neuro-oncology. This article was previously posted to the Research Square preprint server on September 8, 2023.
Materials and methods
Ethical considerations
Approval for the study (2023-04/38) was obtained from the local ethics committee. Patients provided informed consent before receiving contrast-enhanced brain MRI scans. An informed consent form for this study was not requested from the patients due to the retrospective nature of the study.
Patient selection
Between January 2015 and March 2023, a retrospective evaluation was conducted among 1087 patients of both sexes, aged 18-99 years, who underwent cranial MRI at our hospital’s radiology department for preliminary diagnosis of intracranial malignancy. Two radiologists, with six and 10 years of experience in MRI examination, assessed the relationship between primary and metastatic tumors with the fornix. A neuroradiologist with 20 years of experience was consulted to decide inclusion/exclusion when there was uncertainty about the relationship of the tumors with the fornix.
Patients with primary and metastatic tumors involving the fornix were included in the study, and patients whose MRI scan was not of diagnostic quality and whose fornix was not involved were excluded.
MRI evaluations
MRI studies were conducted with a high-field system (1.5T, SIGNA Explorer GE Healthcare, USA) with a dedicated 16-channel head-neck coil. MRI data were acquired using the following sequences: (1) axial T1-weighted imaging sequence with TE/TR, 8/509 msec; slice thickness, 4 mm; matrix size, 224 × 224; FOV, 220 × 220 mm2; (2) axial T2-weighted imaging sequence with TE/TR, 127/4082 msec; slice thickness, 4 mm; matrix size, 416 × 416; FOV, 220 × 220 mm2; (3) sagittal T2-weighted imaging sequence with TE/TR, 114/5638 msec; slice thickness, 4 mm; matrix size, 352 × 352; FOV, 240 × 240 mm2; (4) coronal T2* GRE weighted imaging sequence with TE/TR, 18/660 msec; slice thickness, 5 mm; matrix size, 320 × 192; FOV, 230 × 230 mm2; (5) axial fluid-attenuated inversion recovery (FLAIR) sequence with TE/TR, 104/9000 msec; slice thickness, 4 mm; matrix size, 288 × 192; FOV, 220 × 220 mm2; (6) axial diffusion weighted images with TE/TR, 93/7702 msec; slice thickness, 4 mm; matrix size, 160 × 160; FOV, 220 × 220 mm2; (7) axial post-contrast T1-weighted imaging sequence with TE/TR, 8/509 msec; slice thickness, 4 mm; matrix size, 224 × 224; FOV, 220 × 220 mm2; (8) post-contrast 3D sagittal T1 cube sequence with TE/TR, 13/502 msec; slice thickness, 1.2 mm; matrix size, 320 × 192; FOV, 256 × 256 mm2; (9) coronal FLAIR sequence with TE/TR, 81/9000 msec; slice thickness, 3 mm; matrix size, 320 × 192; FOV, 240 × 240 mm2.
Post-contrast thin-sliced sagittal, axial, and coronal images obtained from 3D sequences were preferred for the evaluation of fornix lesions. The presence of enhancement on post-contrast T1-weighted images was determined as a criterion for fornix involvement. However, hyperintensity on FLAIR images in gliomas without contrast enhancement was considered as fornix involvement.
Results
Fornix involvement was diagnosed in 29/1087 (2.66%) patients (18 males and 11 females; age range, 22-79 years) after retrospective evaluation of cranial MRI scans. The lesions were classified into two main groups: primary and metastatic lesions.
Assessment of metastatic tumors
Of the 29 cases of fornix involvement, 14 (48.2%) were due to metastatic disease, with seven patients having metastatic lesions localized to the fornix and seven patients having metastatic lesions localized to the fornix with adjacent structures. The majority of primary tumors were lung and breast cancer, with other primary tumors including osteosarcoma, renal cell carcinoma, pancreatic adenocarcinoma, gluteal pleomorphic sarcoma, and diffuse large B-cell lymphoma.
Two patients had more than one fornix metastasis, with four metastases located on the crura (two on the right and two on the left) in the patient diagnosed with small-cell lung cancer and two metastases found on the left fornix in the patient with pancreatic adenocarcinoma. In a patient with lung adenocarcinoma, a single fornix lesion involved the bilateral body of the fornix, whereas other patients had a single fornix metastasis. Metastatic lesions were most commonly found in the posterior compartments of the fornix (Figure 1).
Figure 1
Metastatic lesions
(A) Post-contrast axial T1-weighted image showing metastatic lesion localized in the right crus of the fornix (white arrows) in a 60-year-old male with a history of lung adenocarcinoma. (B) Post-contrast coronal T1-weighted image showing two metastatic lesions localized in the bilateral crus of the fornix in a 69-year-old male with a history of small-cell lung cancer (white arrows). 2.0× magnified images of the lesions are shown in the upper left corner.
Metastatic lesions occurred over a wide time interval among the study sample, from the time of diagnosis to 120 months after diagnosis. All patients presented with other intracranial and distant metastases by the time fornix metastasis was identified. In the retrospective review of medical reports, one patient had a memory deficit; except for one patient, all patients had nonspecific clinical symptoms. Clinical and radiological features of the metastatic lesions are summarized in Table 1.
Table 1
Radiologic and clinical features of fornix metastases
M, male; F, female; TOD, at the time of diagnosis; NSS, nonspecific symptoms; R, right; L, left; ER+, estrogen receptor-positive; PR+, progesterone receptor-positive; ALK, anaplastic lymphoma kinase mutation; EGFR, epidermal growth factor receptor mutation
Patient no. | Age(y); gender | Primary tumor; subtype | Lateralization; location | Identified time interval (month) | Distant metastasis | Symptom |
1 | 60; M | Lung cancer; adenocarcinoma | R; crus | 67 | Contralateral lung, lymph node | NSS |
2 | 61; F | Breast cancer; invasive ductal carcinoma ER+ PR+ | R; body | 6 | Lung, liver, bone | Memory deficit |
3 | 49; M | Lung cancer; adenocarcinoma ALK+ | R, L; body | 60 | Lymph node | - |
4 | 46; F | Breast cancer; invasive ductal carcinoma ER+ PR+ | R; crus | 13 | Spinal leptomeningeal metastasis | NSS |
5 | 69; M | Lung cancer; small-cell lung cancer | R, L; body, crus | TOD | Contralateral lung | - |
6 | 64; M | Pancreas; adenocarcinoma | L; body, crus | 10 | Liver, bone, lymph node | - |
7 | 51; M | Diffuse large B-cell lymphoma | L; crus | 8 | Lymph node involvement | - |
8 | 54; F | Breast cancer; invasive ductal carcinoma ER+ PR+ | L; crus-fimbria with hippocampus | 23 | Liver, lung, bone | - |
9 | 56; F | Breast cancer; invasive ductal carcinoma ER+ PR+ | L; crus-fimbria with parietooccipital lobe | 48 | Liver, lung, bone | - |
10 | 57; M | Lung cancer; adenocarcinoma | L; crus with parietooccipital lobe | 120 | Bone | - |
11 | 72; M | Lung cancer; adenocarcinoma ALK- EGFR- | L; crus-fimbria with thalamus | TOD | Adrenal, lymph node | NSS |
12 | 79; M | Renal cell carcinoma; clear cell carcinoma | R; crus-fimbria with temporal lobe | 115 | Lung | - |
13 | 22; M | Osteosarcoma | R; crus-fimbria with parietal lobe | 19 | Lung | - |
14 | 49; F | Pleomorphic sarcoma | L; crus-fimbria with hypothalamus | 67 | Lung | NSS |
However, all patients with fornix metastases also had supratentorial and infratentorial multiple metastatic lesions, and other organ and system metastases were detected. When metastatic lesions were evaluated completely, estrogen receptor positivity and progesterone receptor positivity were found with fornix metastasis in all patients with breast cancer, except for one medical record that could not be accessed.
Assessment of primary brain tumors
Fornix invasion was present in 15 patients (51.7%; age range, 25-78 years) diagnosed with a primary brain tumor. Glioblastoma was the most common primary brain tumor invading the fornix, with other diagnoses including diffuse astrocytoma, medulloblastoma, and anaplastic oligodendroglioma (Figure 2).
Figure 2
Primary tumors
(A) Post-contrast T1-weighted image showing recurrent lesion invading the left crus of the fornix (arrow) in a 56-year-old male diagnosed with glioblastoma. (B) Post-contrast fluid-attenuated inversion recovery (FLAIR) image showing lesion crossing midline via the corpus callosum and invading the bilateral crus of the fornix (arrow) in a 45-year-old male diagnosed with diffuse astrocytoma. (C) Post-contrast T1-weighted image showing recurrent lesion invading both the crus and the body of the left fornix (arrow) in a 25-year-old male diagnosed with medulloblastoma. 2.0× magnified images of the lesions are shown in the upper left corner.
Fornix invasion was present in the MRI studies of eight patients at the time of diagnosis, whereas fornix invasion was detected in recurrent lesions in seven patients five to 91 months after diagnosis. Eight of the fornix-invading primary brain tumors crossed the midline.
Memory deficit was found in three patients, and others had nonspecific symptoms. Clinical and radiological features of primary brain tumors that invaded the fornix are summarized in Table 2.
Table 2
Radiologic and clinical features of primary brain tumors that invade the fornix
M, male; F, female; R, right; L, left; TOD, at the time of diagnosis; NSS, nonspecific symptoms
Patient no. | Age(y); gender | Primary tumor | Lateralization; location | Identified time interval (month) | Symptom | Crossing midline |
1 | 52; M | Glioblastoma | R; crus-fimbria | TOD | NSS | + |
2 | 52; M | Glioblastoma | L; crus-fimbria | Recurrent-10 | Memory deficit | + |
3 | 56; M | Glioblastoma | L; crus-fimbria | TOD | NSS | - |
4 | 38; M | Glioblastoma | L; crus-fimbria | TOD | NSS | + |
5 | 78; M | Glioblastoma | R, L; column and body | TOD | Memory deficit | + |
6 | 56; M | Glioblastoma | L; crus-fimbria | TOD | NSS | - |
7 | 57; F | Glioblastoma | L; column | Recurrent-26 | NSS | + |
8 | 64; M | Glioblastoma | R, L; column | Recurrent-24 | NSS | + |
9 | 55; F | Glioblastoma | L; crus-fimbria, body | Recurrent-22 | NSS | - |
10 | 50; F | Glioblastoma | R, L; column | Recurrent-5 | NSS | + |
11 | 53; F | Glioblastoma | L; crus-fimbria, body | Recurrent-13 | Memory deficit | - |
12 | 25; M | Medulloblastoma | L; crus-body | Recurrent-91 | NSS | + |
13 | 63; M | Anaplastic oligodendroglioma | R; crus-fimbria | Recurrent-14 | - | + |
14 | 45; M | Diffuse astrocytoma | R, L; crus-fimbria | TOD | - | + |
15 | 69; F | Diffuse astrocytoma | L; crus-fimbria | TOD | NSS | - |
Discussion
The fornix may be affected in non-tumoral diseases (e.g., infection, multiple sclerosis, Wernicke’s encephalopathy, mesial temporal sclerosis, trauma-surgery, and infarction), with memory deficit as one possible clinical manifestation [6-11]. Lymphoma and glioblastoma, which are defined as midline tumors, are the most well-known tumors affecting the fornix. It has been argued that these lesions mainly involve corpus callosum involvement in the midline and subsequently spread to the fornix [12,13]. Diffuse astrocytoma is the other reported primary brain tumor that invades the fornix [14]. In this study, we included tumoral lesions affecting the fornix. Our results showed that 14 of 1087 (1.28%) patients had fornix metastasis, and 15 of 1087 (1.37%) patients were diagnosed with primary brain tumors that invade fornix.
In the current study, we showed that in addition to glioblastoma and lymphoma, diffuse astrocytoma, medulloblastoma, and oligodendroglioma can invade the fornix. Although it has been reported that the fornix can be involved in the spread of tumors that cross the midline [12], in the current study, the fornix was invaded by tumors located unilaterally in almost half of the patients diagnosed with primary brain tumors.
We found lesions that metastasized to the fornix and metastatic lesions that invaded the fornix with adjacent structures in 15 patients. To the best of our knowledge, this was the first study evaluating fornix metastasis in the English literature. The primary tumors metastasizing to the fornix originated from the lung, breast, pancreas, and kidney. Primary tumors constituted a more heterogeneous group in metastatic lesions invading the fornix. Metastatic lesions affecting the fornix were detected over a broad timeline, spanning at the time of diagnosis up to 120 months after diagnosis.
Due to the thin formation and close association of the fornix with neighboring structures, it can sometimes be difficult to evaluate with imaging. However, neuroimaging findings and clinical symptom association provide important information about the function of the fornix. MRI examinations of the fornix and other components of the limbic system are frequently conducted in Alzheimer’s disease. [15]. In addition, volumetric examinations of the fimbria fornix have revealed the effect of the right fimbria on spatial memory [16]. When non-metastatic tumoral lesions were evaluated in the current study, one patient with a diagnosis of astrocytoma and one with glioblastoma had memory deficits at the time of diagnosis. In these patients, there was also the involvement of the fornix and other components of the limbic lobe. In one patient diagnosed with glioblastoma, at the time of diagnosis, another limbic-lobe-component invasion was present apart from the fornix, with memory deficit developing after left crus-fimbria invasion.
In addition to the importance of the fornix in cognitive functions and emotional effectiveness, it also has a critical role in memory. The function of the fornix has also become clearer as a result of neuroimaging findings with clinical correlation [17-19]. In our retrospective evaluation made from patient medical records, memory deficit was detected in one patient diagnosed with breast cancer metastasizing to the right fornix body, whereas nausea, vomiting, and headache were found in four patients, with these symptoms nonspecific to the fornix. However, although information covering disease progression and regression was included in the medical records, symptoms were not included except for four patients with fornix involvement. This situation constitutes the most important limitation of our study. Specifically, lesions that metastasize to the fornix were found with multiple brain metastases; the clinical findings of these metastatic lesions may not have been recorded, as they may have overshadowed the memory-related findings.
In our study, we found hormone receptor positivity in patients with breast cancer metastasizing to the fornix, with the exception of one patient whose medical record was inaccessible. Apart from this finding, no common histopathological finding was found in other patient groups.
It should be noted that MRI evaluation of the fornix isn’t easy due to its thin structure and its close proximity to adjacent structures; post-contrast thin-slice images, preferably obtained from 3D sequences, provided great convenience for the anatomical identification of the fornix [20]. The continuity of the fornix and its relationship with neighboring structures (e.g., internal cerebral veins) play an important role in anatomical localization. However, focal enlargement of the internal cerebral vein mimicked fornix metastasis in one patient, who was subsequently excluded from the study. Thus, vascular enlargement may be a potential pitfall in MRI evaluation of the fornix. Collaborative efforts between neuroimaging specialists, neurosurgeons, oncologists, and neuropsychologists could facilitate a holistic understanding of fornix involvement in intracranial tumors, leading to improved patient care and outcomes.
Our study has potential limitations. The study’s retrospective design and relatively small sample size may limit the generalizability of its findings. Future research with larger, more diverse cohorts could provide a more comprehensive understanding of fornix involvement in intracranial tumors. In addition, this study acknowledges the importance of follow-up imaging in assessing fornix involvement over time but does not provide longitudinal data on disease progression or treatment outcomes. Incorporating longitudinal studies could elucidate the natural history of fornix lesions and inform treatment strategies.
Conclusions
In this study, we reported eight years of experience with the fornix, aiming to contribute to the literature on the fornix and limbic systems. The fornix can be affected by both metastatic and non-metastatic intracranial tumors. Although breast and lung cancers were the most common metastatic lesions, glioblastoma was the most common primary brain tumor invading the fornix. Invasion of the fornix was demonstrated in follow-up imaging and imaging at the time of diagnosis.
Knowing the neuroanatomical relationships facilitates the evaluation of lesions affecting the fornix. However, in the presence of a lesion affecting the fornix, accurate reporting of the lesion is important in the clinical correlation of cognitive function and memory deficit. Assessment of symptoms and imaging findings can both help understand the impact of the fornix on cognitive function.
There are opportunities for improvement, particularly in terms of methodological rigor and longitudinal data collection. By addressing these limitations and fostering multidisciplinary collaboration, future research can advance our understanding of fornix pathology and inform evidence-based approaches to patient management in neuro-oncology.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Copyright © 2024, Kılıç et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Background
The aim of this study is to evaluate the clinical and radiological findings of metastatic tumors and primary brain tumors affecting the fornix.
Methods
Between January 2015 and March 2023, we retrospectively evaluated 1087 patients of both sexes who underwent cranial magnetic resonance imaging (MRI) for a preliminary diagnosis of intracranial malignancy in the radiology department of our hospital. Two radiologists with six and 10 years of experience in MRI examination assessed the relationship between primary and metastatic tumors and the fornix.
Results
Involvement of the fornix was diagnosed in 29 of the 1087 patients (2.66%), of which fornix was affected by metastatic lesions in 14 patients (48.2%) and primary tumors in 15 patients (51.7%). The majority of metastatic lesions were from lung and breast cancers, with other tumor types including osteosarcoma, renal cell carcinoma, pancreatic adenocarcinoma, pleomorphic sarcoma, and diffuse large B-cell lymphoma. Among all primary tumors, glioblastoma was the most common primary brain tumor invading the fornix, with other diagnoses including diffuse astrocytoma, medulloblastoma, and anaplastic oligodendroglioma. Metastatic and primary brain tumors affecting the fornix were detected over a broad timeline, from the time of diagnosis up to 120 months after diagnosis. A retrospective evaluation of medical records revealed memory deficits in four patients.
Conclusion
The fornix can be affected by both metastatic and primary brain tumors. It is crucial to understand the relevant neuroanatomical relationships when evaluating lesions that affect the fornix.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer